Gilead Sciences, Inc.
GILD
|
$66.16
-1.15%
-1.16%
6.4M
|
Health Technology
(0.0% 1d) (-8.8% 1m) (-20.4% 1y) (0.0% 2d) (-0.6% 3d) (-1.7% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 82,374,308,809
http://www.gilead.com
Sec Filling | Patents | 11800 employees
(US) Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
respiratory liver urea antiviral brands liver disease respiratory diseases
Drugs
Biktarvy (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate)Cayston (aztreonam)
COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)
DESCOVY (emtricitabine and tenofovir alafenamide)
Emtriva (EMTRICITABINE)
Epclusa (Velpatasvir and Sofosbuvir)
Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
Hepsera (adefovir dipivoxil)
ODEFSEY (emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide)
Ranexa (RANOLAZINE)
Sovaldi (SOFOSBUVIR)
Stribild (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Tybost (COBICISTAT)
Veklury (REMDESIVIR)
VEMLIDY (tenofovir alafenamide)
Viread (TENOFOVIR DISOPROXIL FUMARATE)
Vosevi (SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR)
Zydelig (idelalisib)
add to watch list Paper trade email alert is off
Press-releases
Gilead Sciences Publishes 2023 ESG Impact Report
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
gilead report sciences impact esg
Leap Therapeutics Announces $40 Million Private Placement
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
LPTX | $2.96 -1.33% -1.35% 100K
|
Health Technology
|
| O: 15.13%
H: 25.43%
C: -11.0%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
million leap therapeutics
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.8 -1.99% -2.02% 6.3M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Published: 2024-04-08 (Crawled : 13:30) - prnewswire.com
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: -1.5%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.76%
H: 0.72%
C: 0.54%
biopharma results
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
Published: 2024-04-08 (Crawled : 23:00) - biospace.com/
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.76%
H: 0.72%
C: 0.54%
gilead first sciences financial results
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
Published: 2024-04-02 (Crawled : 20:00) - globenewswire.com
RMD | $177.61 2.18% 0.0% 1.6M
|
Health Technology
|
| O: 0.88%
H: 1.64%
C: 0.03%
LUNG | $7.5 0.94% 0.93% 540K
|
Health Technology
|
| O: 0.59%
H: 1.64%
C: -7.13%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.12%
H: 0.24%
C: -1.54%
financial
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -1.0%
business year pipeline therapeutics financial results
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
Published: 2024-03-29 (Crawled : 18:00) - prnewswire.com
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
| Email alert
Add to watchlist
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
GNMSF | $281.02 3.83% 210
|
Health Technology
| Email alert
Add to watchlist
research global leukemia therapeutics market
Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
ASMB | $12.95 0.23% 0.23% 17K
|
Health Technology
| Email alert
Add to watchlist
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
| Email alert
Add to watchlist
year financial results
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
XLO | $1.23 0.0% 150K
|
Professional, Scientific, and T...
|
| O: 200.47%
H: 0.52%
C: -43.75%
GILD | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: 0.33%
H: 0.85%
C: 0.0%
million therapeutics
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
SNDA P 3000 | $29.61 3.35% 0.0% 30K
|
n/a
|
22:00
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
FAST P 3350 | $67.5 -1.43% -1.45% 3.6M
|
Distribution Services
|
20:00
QCRH | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
RVP P 15363 | $1.05 0.96% 0.0% 120K
|
Health Technology
|
18:00
VUZI | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
TPL P 3 | $582.4 -0.44% 0.0% 63K
|
Miscellaneous
|
15:00
RELL | $10.15 2.94% 2.86% 94K
|
Electronic Technology
|
13:30
IZEA | $2.65 4.74% 4.53% 31K
|
Technology Services
|
00:00
RKT P 383 | $11.53 1.32% 0.0% 1.6M
|
Finance
|
22:30
CTRN P 18090 | $22.28 -0.4% -0.4% 55K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% -0.36% 54K
|
Energy Minerals
|
21:00
NEOG P 10000 | $11.94 -1.65% -1.68% 2.9M
|
Health Technology
|
16:30
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10